Swati Kumar

Swati Kumar

Auto-generated profile, based on publicly available information

Swati Kumar

Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, Northern Ireland, United Kingdom

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
SKSwati Kumar
Swati Kumar
CFCiaran Fairmichael
Ciaran Fairmichael
DLDaniel B. Longley
Daniel B. Longley
RTRichard C Turkington
Richard C Turkington

1 November 2017 in OMICS: A Journal of Integrative Biology
Verified
Journal Article
Closed access
MJManali Jadhav
Manali Jadhav
MNMonalisha Nayak
Monalisha Nayak
SKSwati Kumar
Swati Kumar
AVApoorva Venkatesh
Apoorva Venkatesh
SPSandip K. Patel
Sandip K. Patel
Sanjeeva SrivastavaSanjeeva Srivastava
Sanjeeva Srivastava
Dengue fever (DF) is a major global health burden with a pathophysiology that is still incompletely understood. Biomarkers that predict and explain susceptibility to DF and its progression to its more severe hemorrhagic form are much needed. DF is endemic in tropical and subtropical regions of the world, with a rapidly increasing incidence of disease severity. We conducted a clinical biomarker discovery study using both a case–control and longitudinal study design. Plasma proteome alterations in patients with DF ( n = 12) and dengue hemorrhagic fever (DHF, n = 24) were analyzed in comparison to healthy controls (HCs, n = 16), using the isobaric tags for relative and absolute quantification (iTRAQ)-based quantitative proteomics methodology (false discovery rate of 1%, ≥2 peptides). Several proteins such as the alpha-2 macroglobulin, angiotensinogen, apolipoprotein B-100, serotransferrin, and ceruloplasmin were upregulated (fold change >1.2) in all DHF cases, and downregulated in DF (fold change <0.83), compared with HCs. Plasma cytokine profiling (8 DF, 8 DHF, and 8 HC) on two consecutive time points, at day 0 (day of admission) and days 5–7, found significant elevation in IL-1RA, IL-7, TNF-α, MCP1-MCAF, and MIP-1β levels, but only in the DHF cases, which is the severe disease, and not in DF, compared with HCs ( p < 0.05). These new observations on changes in the plasma proteome and cytokine profiles in patients with dengue infection identify several putative molecular leads for future biomarker development and precision medicine in relation to forecasting DF disease severity.

2 March 2020 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
AVApoorva Venkatesh
Apoorva Venkatesh
SAShalini Aggarwal
Shalini Aggarwal
SKSwati Kumar
Swati Kumar
SRSrushti Rajyaguru
Srushti Rajyaguru
VKVipin Kumar
Vipin Kumar
Sanjeeva SrivastavaSanjeeva Srivastava
Sanjeeva Srivastava
Background: In recent times,Plasmodium vivax (P. vivax)has become a serious threat to public health due to its ability to cause severe infection with fatal outcomes. Its unique biology makes it resilient to control measures that are otherwise effective againstP. falciparum. A deeper understanding ofP. vivaxbiology and pathogenesis is, therefore, essential for developing the right control strategies. Proteomics ofP. falciparumhas been helpful in studying disease biology and elucidating molecular mechanisms involved in the development of disease. However, unlikeP. falciparum, proteomics data forP. vivaxinfection is minimal due to the absence of a continuous culture system. The dependence on clinical samples and animal models has drastically limitedP. vivaxresearch, creating critical knowledge gaps in our understanding of the disease. This study describes an in-depth proteomics analysis ofP. vivax-infected human plasma and parasite isolates, to understand parasite biology, pathogenesis, and to identify new diagnostic targets forP. vivaxmalaria.Methods: A mass-spectrometry- (MS) based proteomics approach (Q Exactive) was applied to analyze human plasma and parasite isolates from vivax malaria patients visiting a primary health centre in India. Additionally, a targeted proteomics assay was standardized for validating unique peptides of most recurring parasite proteins.Results: Thirty-eightP. vivaxproteins were detected in human plasma with high confidence. Several glycolytic enzymes were found along with hypothetical, cytoskeletal, ribosomal, and nuclear proteins. Additionally, 103 highly abundantP. vivaxproteins were detected in parasite isolates. This represents the highest number of parasite proteins to be reported from clinical samples so far. Interestingly, five of these; threePlasmodiumexported proteins (PVX_003545, PVX_003555 and PVX_121935), a hypothetical protein (PVX_083555) and Pvstp1 (subtelomeric transmembrane protein 1, PVX_094303) were found in both plasma and parasite isolates.Conclusions: A parasite proteomics investigation is essential to understand disease pathobiology and design novel interventions. Control strategies againstP. vivaxalso depend on early diagnosis. This work provides deeper insights into the biology ofP. vivaxby identifying proteins expressed by the parasite during its complex life-cycle within the human host. The study also reports antigens that may be explored as diagnostic candidates.

22 November 2021 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
PDF file
SKSwati Kumar
Swati Kumar
RSRalph J. Santos
Ralph J. Santos
AMAndrew J. McGuigan
Andrew J. McGuigan
USUrvashi Singh
Urvashi Singh
PJPeter Johnson
Peter Johnson
RTRichard C Turkington
Richard C Turkington
Background: Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, and this is attributed to it being diagnosed at an advanced stage. Understanding the pathways involved in initial development may improve early detection strategies. This systematic review assessed the association between circulating protein and metabolite biomarkers and PDAC development. Methods: A literature search until August 2020 in MEDLINE, EMBASE, and Web of Science was performed. Studies were included if they assessed circulating blood, urine, or salivary biomarkers and their association with PDAC risk. Quality was assessed using the Newcastle-Ottawa scale for cohort studies. Random-effects meta-analyses were used to calculate pooled relative risk. Results: A total of 65 studies were included. Higher levels of glucose were found to be positively associated with risk of developing PDAC [n = 4 studies; pooled relative risk (RR): 1.61; 95% CI: 1.16–2.22]. Additionally, an inverse association was seen with pyridoxal 5′-phosphate (PLP) levels (n = 4 studies; RR: 0.62; 95% CI: 0.44–0.87). Meta-analyses showed no association between levels of C-peptide, members of the insulin growth factor signaling pathway, C-reactive protein, adiponectin, 25-hydroxyvitamin D, and folate/homocysteine and PDAC risk. Four individual studies also reported a suggestive positive association of branched-chain amino acids with PDAC risk, but due to differences in measures reported, a meta-analysis could not be performed. Conclusions: Our pooled analysis demonstrates that higher serum glucose levels and lower levels of PLP are associated with risk of PDAC. Impact: Glucose and PLP levels are associated with PDAC risk. More prospective studies are required to identify biomarkers for early detection.

26 November 2025
Verified
Other
Open access
SKSwati Kumar
Swati Kumar
RSRalph J. Santos
Ralph J. Santos
AMAndrew J. McGuigan
Andrew J. McGuigan
USUrvashi Singh
Urvashi Singh
PJPeter Johnson
Peter Johnson
RTRichard C. Turkington
Richard C. Turkington
Supplementary Data from The Role of Circulating Protein and Metabolite Biomarkers in the Development of Pancreatic Ductal Adenocarcinoma (PDAC): A Systematic Review and Meta-analysis

26 November 2025
Verified
Other
Open access
SKSwati Kumar
Swati Kumar
RSRalph J. Santos
Ralph J. Santos
AMAndrew J. McGuigan
Andrew J. McGuigan
USUrvashi Singh
Urvashi Singh
PJPeter Johnson
Peter Johnson
RTRichard C. Turkington
Richard C. Turkington
Supplementary Data from The Role of Circulating Protein and Metabolite Biomarkers in the Development of Pancreatic Ductal Adenocarcinoma (PDAC): A Systematic Review and Meta-analysis